High Cholesterol

Clinical Trial Finder

Many patients with high cholesterol are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C

Condition:   Hypercholesterolemia
Interventions:   Drug: Bempedoic acid 180mg;   Drug: Ezetimibe 10mg;   Drug: Atorvastatin 20mg;   Other: Placebo
Sponsor:   Esperion Therapeutics
Recruiting - verified February 2017

Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)

Condition:   Heterozygous Familial Hypercholesterolemia
Interventions:   Drug: MGL-3196;   Drug: Placebo
Sponsor:   Madrigal Pharmaceuticals, Inc.
Recruiting - verified February 2017

Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo

Condition:   Hypercholesterolemia
Interventions:   Drug: Praluent (Alirocumab);   Drug: Placebo
Sponsors:   Regeneron Pharmaceuticals;   Sanofi
Recruiting - verified February 2017

Alirocumab in Patients With Acute Myocardial Infarction

Conditions:   Myocardial Infarction;   Hypercholesterolemia
Interventions:   Drug: alirocumab;   Drug: placebo
Sponsors:   Virginia Commonwealth University;   Regeneron Pharmaceuticals;   Sanofi
Recruiting - verified February 2017

Comprehensive Treatment of Angina in Women With Microvascular Dysfunction

Conditions:   Angina Pectoris;   Coronary Microvascular Disease
Interventions:   Dietary Supplement: Diet;   Behavioral: Training;   Drug: Medication (with statin and ACE-inhibition)
Sponsors:   Bispebjerg Hospital;   University Hospital Bispebjerg and Frederiksberg;   Cambridge Weight Plan Limited
Recruiting - verified February 2017

An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

Condition:   Hypercholesterolaemia
Interventions:   Drug: alirocumab SAR236553 (REGN727);   Drug: statins;   Drug: ezetimibe;   Drug: cholestyramine;   Drug: fenofibrate;   Drug: omega-3 fatty acids;   Drug: nicotinic acid
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified February 2017

Study to Evaluate the Safety of Repatha® in Pregnancy

Conditions:   Hypercholesterolaemia;   Pregnancy
Intervention:  
Sponsor:   Amgen
Recruiting - verified February 2017

Chart Review of Repatha® in Subjects With Hyperlipidaemia

Condition:   Hypercholesterolaemia
Intervention:  
Sponsor:   Amgen
Recruiting - verified February 2017

Graves' Orbitopathy and Hypercholesterolemia

Conditions:   Graves' Ophthalmopathy;   Hypercholesterolemia
Intervention:   Other: No intervention
Sponsor:   University of Pisa
Recruiting - verified February 2017

Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia

Condition:   Hypercholesterolemia
Interventions:   Drug: alirocumab SAR236553 (REGN727);   Drug: placebo for alirocumab;   Drug: ezetimibe;   Drug: placebo for ezetimibe;   Drug: atorvastatin;   Drug: rosuvastatin;   Drug: simvastatin
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified February 2017

A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH)

Condition:   Homozygous Familial Hypercholesterolemia
Intervention:   Biological: AAV directed hLDLR gene therapy
Sponsor:   University of Pennsylvania
Recruiting - verified January 2017

Trial Assessing Evolocumab(AMG145) Compared to LDL-C Apheresis in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment

Condition:   Hypercholesterolemia
Interventions:   Biological: evolocumab (AMG 145);   Other: Low Density Lipoprotein Cholesterol (LDL-C) Apheresis
Sponsor:   Amgen
Completed - verified February 2017

Lipid-lowering Effect of Phytosterols, Red Yeast Rice and Their Combination

Condition:   Hypercholesterolemia
Interventions:   Dietary Supplement: Plant sterols;   Dietary Supplement: Red Yeast Rice;   Dietary Supplement: Red Yeast Rice plus Plant sterols
Sponsor:   University of Bologna
Completed - verified February 2017

A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384)

Conditions:   Hypercholesterolemia;   Heterozygous Familial Hypercholesterolemia
Interventions:   Drug: EZ 10 mg/Atorva 20 mg FDC;   Drug: EZ 10 mg/Atorva 10 mg FDC
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified February 2017

Trial Assessing Efficacy, Safety and Tolerability of PCSK9 Inhibition in Paediatric Subjects With Genetic LDL Disorders

Condition:   Heterozygous Familial Hypercholesterolemia
Interventions:   Drug: Evolocumab;   Drug: Placebo
Sponsor:   Amgen
Recruiting - verified February 2017

Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events

Condition:   Hyperlipidemia
Interventions:   Drug: Bococizumab (PF-04950615;RN316);   Other: Placebo
Sponsor:   Pfizer
Completed - verified February 2017

Gene Analysis and Treatment Optimization in Chinese Homozygous Familial Hypercholesterolemia

Condition:   Homozygous Familial Hypercholesterolemia
Interventions:   Genetic: Gene analysis;   Other: Historical data of lipid-lowering drug administration;   Other: Historical data of plasma lipids, xanthoma changes
Sponsor:   Central South University
Completed - verified February 2017

Study of a Holistic Health Program for United Methodist Clergy

Conditions:   Obesity;   Depression;   Diabetes;   Hypertension;   Hypercholesterolemia
Intervention:   Behavioral: Holistic health
Sponsors:   Duke Clergy Health Initiative;   The Duke Endowment
Completed - verified February 2017

Functional and Cognitive Impairment in Advanced Kidney Disease

Condition:   Kidney Insufficiency, Chronic
Intervention:  
Sponsor:   VA Office of Research and Development
Active, not recruiting - verified February 2017

Heart Outcomes Prevention Evaluation-3

Conditions:   Cardiovascular Disease;   Stroke
Interventions:   Drug: Candesartan/HCT;   Drug: Rosuvastatin
Sponsor:   Population Health Research Institute
Completed - verified February 2017

Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054)

Conditions:   Hypercholesterolemia;   Hyperlipidemia
Interventions:   Drug: niacin (+) laropiprant;   Drug: niacin
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified February 2017

Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED)

Conditions:   Hypercholesteremia;   Hyperlipidemia
Interventions:   Drug: MK-0524A;   Drug: ER Niacin;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified February 2017